ClinicalTrials.gg
CompletedNCT02126358Updated Oct 18, 2016

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

A Phase 3 interventional study of Gemigliptin and/or Rosuvastatin in Type 2 Diabetes and Dyslipidemia, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2016-10-18.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
5th of 18
290 · median 130
Started
2014
with 4 others
Phase 3
9 of 18
none open now
Registered
6th of 18
by date
Lead sponsor
8 of 18
LG Life Sciences

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 5 that started in 2014, is one of 9 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia

03

Conditions studied

  • Type 2 Diabetes
  • Dyslipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus with Dyslipidemia
  • Adults who are at least 19 years old

Exclusion criteria

Exclusion Criteria:

  • Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and pre-coma
  • Patients with gestational diabetes or secondary diabetes
  • Patients with Class III, IV congestive heart failure or arrhythmias requiring treatment
  • Patients with thyroid gland dysfunction deviating from the normal TSH range
  • Patients with pituitary insufficiency or adrenal insufficiency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
290 participants (actual)

Study arms

  • Placebo comparator
    Gemigliptin

    only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)

    Drug: Gemigliptin and/or Rosuvastatin

  • Placebo comparator
    Rosuvastatin

    only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)

    Drug: Gemigliptin and/or Rosuvastatin

  • Experimental
    FDC

    Gemigliptin \& Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)

    Drug: Gemigliptin and/or Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c change

    Time frame: Baseline(Day 0) to Treatment (last visit, w24)

  2. LDL-C change rate

    Time frame: Baseline(Day 0) to Treatment (last visit, w24)

Secondary outcomes

  1. HbA1c

    (Gemigliptin/Rosuvastatin FDC vs. Gemigliptin)

    Time frame: Baseline(Day 0) to Treatment (last visit, w24)

  2. LDL-C change rate

    (Gemigliptin/Rosuvastatin FDC vs. Rosuvastatin)

    Time frame: Baseline(Day 0) to Treatment (last visit, w24)

07

Study locations

1 site
  • Severance hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Apr 30, 2014
Start
May 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Oct 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02126358
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Apr 30, 2014
Start date
May 2014
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Oct 18, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemigliptin · Rosuvastatin

Start the discussion